These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2784714)

  • 1. In vivo and in vitro synergistic antitumor effect of interleukin-2-cultured tumor-bearer spleen cells and immune fresh spleen cells.
    Kan N; Okino T; Nakanishi M; Satoh K; Ohgaki K; Tobe T
    Cancer Immunol Immunother; 1989; 28(4):260-6. PubMed ID: 2784714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of polyethylene glycol 6000 on the generation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells cultured in the presence or absence of inactivated stimulator tumor cells.
    Przepiorka D; Mokyr MB; Dray S
    Cancer Res; 1980 Dec; 40(12):4565-70. PubMed ID: 7438090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adoptive immunotherapy of murine tumor using cultured syngeneic tumor-bearer-spleen cells. 1: Anti-tumor activity of tumor-bearer-spleen cells cultured with T cell growth factor (TCGF) and soluble tumor extract].
    Kan N; Inamoto T; Yamasaki N; Hori T; Nio Y; Nakayama N; Kodama H; Ohgaki K
    Nihon Gan Chiryo Gakkai Shi; 1985 Feb; 20(1):31-9. PubMed ID: 3873507
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
    Mokyr MB; Colvin M; Dray S
    Int J Immunopharmacol; 1985; 7(1):111-22. PubMed ID: 3922904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential immunotherapy using interleukin-1 followed by interleukin-2 of ascitic MOPC104E-bearing mice.
    Harada T; Kan N; Okino T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Ohgaki K; Imamura M
    Biotherapy; 1993-1994; 7(2):91-9. PubMed ID: 7803195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Specific antitumor effect of lymphokine-activated lymphocytes obtained from tumor-bearing mice after intratumoral injection of interleukin-2 (IL-2)].
    Takahashi M
    Nihon Geka Gakkai Zasshi; 1991 Mar; 92(3):247-56. PubMed ID: 2051976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
    Mazumder A; Rosenberg SA
    J Exp Med; 1984 Feb; 159(2):495-507. PubMed ID: 6141211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.
    Peppoloni S; Mathieson BJ; Herberman RB; Overton RW; Gorelik E
    Cancer Immunol Immunother; 1987; 24(1):49-56. PubMed ID: 2949833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.
    Kan N; Okino T; Nakanishi M; Sato K; Mise K; Yamasaki S; Teramura Y; Ohgaki K; Tobe T
    Biotherapy; 1989; 1(3):197-206. PubMed ID: 2642023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T; Chang AE; Shu SY
    J Immunol; 1988 Apr; 140(7):2453-61. PubMed ID: 2450925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adoptive immunotherapy of murine tumors using cultured syngeneic tumor-bearer-spleen cells. II: Therapeutic effect of cultured lymphocytes against malignant ascites and its augmentation by the streptococcal preparation, OK 432].
    Kan N; Inamoto T; Hori T; Nio Y; Tsuchitani T; Kodama H; Tobe T; Ohgaki K
    Nihon Gan Chiryo Gakkai Shi; 1985 May; 20(4):784-96. PubMed ID: 3877129
    [No Abstract]   [Full Text] [Related]  

  • 14. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
    Takesue BY; Bartik MM; Mokyr MB
    Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.
    Kan N; Ohgaki K; Inamoto T; Kodama H
    Cancer Immunol Immunother; 1984; 18(3):215-22. PubMed ID: 6334553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
    Rodolfo M; Salvi C; Parmiani G
    Cancer Immunol Immunother; 1989; 28(2):136-42. PubMed ID: 2783888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden.
    Zou JP; Nagata T; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
    J Cancer Res Clin Oncol; 1994; 120(5):279-85. PubMed ID: 7907334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
    Spiess PJ; Yang JC; Rosenberg SA
    J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S; Chou T; Rosenberg SA
    J Immunol; 1986 May; 136(10):3891-8. PubMed ID: 3486223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.
    Gorelik L; Bar-Dagan Y; Mokyr MB
    J Immunol; 1996 Jun; 156(11):4298-308. PubMed ID: 8666801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.